New Pancreatic Cancer Drugs Could Arrive This Year
After decades of slow progress, breakthrough drugs targeting a genetic mutation found in 90% of pancreatic cancers are nearing FDA approval in 2026. The KRAS inhibitors now in late-stage trials could transform treatment for one of medicine's deadliest diseases.
